Corvus Pharmaceuticals
CRVS
52 hedge funds and large institutions have $360M invested in Corvus Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
44% more capital invested
Capital invested by funds: $250M → $360M (+$110M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.79% less ownership
Funds ownership: 83.62% → 82.82% (-0.79%)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
2% less funds holding
Funds holding: 53 → 52 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.86M |
| 3 |
BlackRock
New York
|
+$2.79M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.05M |
| 5 |
Renaissance Technologies
New York
|
+$905K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.81M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.84M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$1.49M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$643K |
| 5 |
Millennium Management
New York
|
-$564K |
CRVS Hedge Fund Activity: Q1 2017 in Review
52 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2017, worth a combined $360M — up 44% from $250M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CRVS positions and 4 closed out — a net gain of 6 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.4M. The largest seller was Fidelity Investments, cutting an estimated $2.81M.
- 52 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2017, down from 53 in Q4 2016.
- Funds reported $360M of Corvus Pharmaceuticals stock for Q1 2017, up 44% quarter-over-quarter.
- 10 funds opened new Corvus Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of +6 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2017 was Point72 Asset Management, an estimated $6.4M added.
- The largest Corvus Pharmaceuticals seller in Q1 2017 was Fidelity Investments, an estimated $2.81M sold.
Based on aggregated 13F filings for Q1 2017.